ALMR Alamar Biosciences, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$20.54

Period return

-1.46 (-6.64%)

Volume

280.0K

2026-06-05O $21.49 H $21.7 L $20.39 C $20.54MA5 $20.86MA20 $21.21

6M · 35 barsYahoo Finance · USD2026-04-17 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 13.MediumBUY25 days ago
Leerink Partners: Outperform
US analyst rating / recommendation change.
2026. 05. 12.MediumBUY25 days ago
TD Cowen: Buy
US analyst rating / recommendation change.
2026. 05. 12.MediumBUY25 days ago
JP Morgan: Overweight
US analyst rating / recommendation change.
2026. 05. 12.MediumBUY25 days ago
Stifel: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $30 · 5 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. The company was incorporated in 2018 and is based in Fremont, California.

Sector: Healthcare
Industry: Medical Devices
HQ: Fremont, CA, United States
Fiscal year end: —
Employees: 222
IPO date: —

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 06.	After market close (AMC)	$-0.32	—	—	$25.94M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-0.68	—	—	$13.09M	Reported

Alamar Biosciences, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 13.	Leerink Partners	—	Initiate coverage	— → Outperform	—	Leerink Partners: Outperform
2026. 05. 12.	TD Cowen	—	Initiate coverage	— → Buy	—	TD Cowen: Buy
2026. 05. 12.	JP Morgan	—	Initiate coverage	— → Overweight	—	JP Morgan: Overweight
2026. 05. 12.	Stifel	—	Initiate coverage	— → Buy	—	Stifel: Buy